Document:

<PAGE>
                                                                   Exhibit 10.19

                               EQUIPMENT SCHEDULE
                           (Quasi Lease - Fixed Rate)
                                SCHEDULE NO. 005
                            DATED THIS DEC. 28, 2001
                           TO MASTER LEASE AGREEMENT
                          DATED AS OF AUGUST 14, 2000

Lessor & Mailing Address:                  Lessee & Mailing Address:
------------------------                   ------------------------
General Electric Capital Corporation       Virologic, Inc.
401 Merritt 7 2nd Floor                    270 EAST GRAND AVENUE
Norwalk, CT 06856                          SOUTH SAN FRANCISCO, CA 94080-

This Schedule is executed pursuant to, and incorporates by reference the terms
and conditions of, and capitalized terms not defined herein shall have the
meanings assigned to them in, the Master Lease Agreement identified above
("Agreement", said Agreement and this Schedule being collectively referred to as
"Lease"). This Schedule, incorporating by reference the Agreement, constitutes a
separate instrument of lease.

A.   EQUIPMENT: Subject to the terms and conditions of the Lease, Lessor agrees
to lease to Lessee the Equipment described below (the "Equipment").

Number      Capitalized                                      Year/Model and Type
of Units    Lessor's Cost   Manufacturer   Serial Numbers       of Equipment

    EQUIPMENT AS LISTED ON EXHIBIT A ATTACHED HERETO AND MADE A PART HEREOF

Equipment immediately listed above is located at: 345 Oyster Point AND 343
Oyster Point, South San Francisco, San Mateo County, CA 94080.

B.   FINANCIAL TERMS

<Table>
<Caption>
<S>  <C>                                          <C>  <C>
--------------------------------------------------------------------------------------------
1.   Advance Rent (if any): $19,451.21.           6.   Lessee Federal Tax ID No.: 943234475.
--------------------------------------------------------------------------------------------
2.   Capitalized Lessor's Cost: $604,233.63.      7.   Last Delivery Date: Dec. 28, 2001.
--------------------------------------------------------------------------------------------
3.   Basic Term (No. of Months): 36 Months.       8.   Daily Lease Rate Factor: .107305.
--------------------------------------------------------------------------------------------
4.   Basic Term Lease Rate Factor: 3.219155       9.   Interest Rate: 10.43% per annum.
--------------------------------------------------------------------------------------------
5.   Basic Term Commencement Date: Jan. 1, 2002.  10.  Option Payment: $101.00
--------------------------------------------------------------------------------------------
</Table>

11.  First Termination Date: THIRTY-SIX (36) months after the Basic Term
     Commencement Date.

12.  Interim Rent: For the period from and including the Lease Commencement Date
     to the Basic Term Commencement Date ("INTERIM PERIOD"), Lessee shall pay
     as rent ("INTERIM RENT") for each unit of Equipment, the product of the
     Daily Lease Rate Factor times the Capitalized Lessor's Cost of such unit
     times the number of days in the Interim Period. Interim Rent shall be due
     on Jan. 1, 2002.

13.  Basic Term Rent. Commencing on Jan. 1, 2002 and on the same day of each
     month thereafter (each, a "RENT PAYMENT DATE") during the Basic Term,
     Lessee shall pay as rent ("BASIC TERM RENT") the product of the Basic Term
     Lease Rate Factor times the Capitalized Lessor's Cost of all Equipment on
     this Schedule.

14.  Lessee agrees and acknowledges that the Capitalized Lessor's Cost of the
     Equipment as stated on the Schedule is equal to the fair market value of
     the Equipment on the date hereof.

C.   INTEREST RATE:  Interest shall accrue from the Lease Commencement Date
     through and including the date of termination of the Lease.

D.   PROPERTY TAX

     APPLICABLE TO EQUIPMENT LOCATED IN CALIFORNIA: Lessee agrees that it will
     (a) list all such Equipment, (b) report all property taxes assessed against
     such Equipment and (c) pay all such taxes when due directly to the
     appropriate taxing authority until Lessor shall otherwise direct in
     writing. Upon request of Lessor, Lessee shall promptly provide proof of
     filing and proof of payment to Lessor.

     Lessor may notify Lessee (and Lessee agrees to follow such notification)
     regarding any changes in property tax reporting and payment
     responsibilities.

E.   ARTICLE 2A NOTICE

     IN ACCORDANCE WITH THE REQUIREMENTS OF ARTICLE 2A FOR THE UNIFORM
     COMMERCIAL CODE AS ADOPTED IN THE APPLICABLE STATE, LESSOR HEREBY MAKES THE
     FOLLOWING DISCLOSURES TO LESSEE PRIOR TO EXECUTION OF THE LEASE. (A) THE
     PERSONS(S) SUPPLYING THE EQUIPMENT IS VARIOUS (THE "SUPPLIER(S)"), (B)
     LESSEE IS ENTITLED TO THE PROMISES AND WARRANTIES, INCLUDING THOSE OF ANY
     THIRD PARTY, PROVIDED TO THE LESSOR BY SUPPLIER(S), WHICH IS SUPPLYING THE
     EQUIPMENT IN CONNECTION WITH OR AS PART OF THE CONTRACT BY WHICH LESSOR
     ACQUIRED THE EQUIPMENT AND (C) WITH

<PAGE>
     RESPECT TO SUCH EQUIPMENT, LESSEE MAY COMMUNICATE WITH SUPPLIER(S) AND
     RECEIVE AN ACCURATE AND COMPLETE STATEMENT OF SUCH PROMISES AND WARRANTIES,
     INCLUDING ANY DISCLAIMERS AND LIMITATIONS OF THEM OR OF REMEDIES. TO THE
     EXTENT PERMITTED BY APPLICABLE LAW. LESSEE HEREBY WAIVES ANY AND ALL RIGHTS
     AND REMEDIES CONFERRED UPON A LESSEE IN ARTICLE 2A AND ANY RIGHTS NOW OR
     HEREAFTER CONFERRED BY STATUTE OR OTHERWISE WHICH MAY LIMIT OR MODIFY ANY
     OF LESSOR'S RIGHTS OR REMEDIES UNDER THE DEFAULT AND REMEDIES SECTION OF
     THE AGREEMENT.

F.   STIPULATED LOSS AND TERMINATION VALUE TABLE*

<Table>
<Caption>
                     Termination         Stipulated                         Termination         Stipulated
                     Value               Loss Value                         Value               Loss Value
      Rental         Percentage          Percentage          Rental         Percentage          Percentage
      Basic
      <S>            <C>                 <C>                 <C>            <C>                 <C>
        1            99.781              103.729              19            53.669              56.158
        2            97.403              101.271              20            50.890              53.298
        3            95.005               98.791              21            48.088              50.415
        4            92.586               96.291              22            45.260              47.506
        5            90.146               93.770              23            42.409              44.574
        6            87.684               91.227              24            39.532              41.616
        7            85.201               88.664              25            36.631              38.634
        8            82.697               86.078              26            33.704              35.626
        9            80.171               83.471              27            30.752              32.592
       10            77.623               80.842              28            27.774              29.534
       11            75.052               78.190              29            24.770              26.449
       12            72.460               75.516              30            21.740              23.338
       13            69.845               72.820              31            18.684              20.200
       14            67.207               70.101              32            15.602              17.037
       15            64.546               67.359              33            12.492              13.846
       16            61.862               64.594              34             9.355              10.628
       17            59.154               61.806              35             6.191               7.383
       18            56.424               58.994              36             3.000               4.111
</Table>

     *The Stipulated Loss Value or Termination Value for any unit of Equipment
     shall be the Capitalized Lessor's Cost of such unit multiplied by the
     appropriate percentage derived from the above table. In the event that the
     Lease is for any reason extended, then the last percentage figure shown
     above shall control throughout any such extended term.

G.   PAYMENT AUTHORITY

     You are herby irrevocably authorized and directed to deliver and apply the
     proceeds due under this Schedule as follows:

<Table>
<Caption>
     COMPANY NAME                  ADDRESS                                 AMOUNT
     ------------                  -------                                 ------
     <S>                           <C>                                     <C>
     VIROLOGIC, INC.               270 East Grand Avenue                   $604,233.63
                                   South San Francisco CA 94080
</Table>

     This authorization and direction is given pursuant to the same authority
     authorizing the above-mentioned financing.

PURSUANT TO THE PROVISIONS OF THE LEASE, AS IT RELATES TO THIS SCHEDULE, LESSEE
HEREBY CERTIFIES AND WARRANTS THAT (I) ALL EQUIPMENT LISTED ABOVE IS IN GOOD
CONDITION AND APPEARANCE, HAS BEEN DELIVERED AND INSTALLED (IF APPLICABLE) AS OF
THE DATE STATED ABOVE AND IN WORKING ORDER; (II) LESSEE HAS INSPECTED THE
EQUIPMENT, AND ALL SUCH TESTING AS IT DEEMS NECESSARY HAS BEEN PERFORMED BY
LESSEE, SUPPLIER OR THE MANUFACTURER; AND (III) LESSEE ACCEPTS THE EQUIPMENT FOR
ALL PURPOSES OF THE LEASE AND ALL ATTENDANT DOCUMENTS.

LESSEE DOES FURTHER CERTIFY THAT AS OF THE DATE HEREOF (I) LESSEE IS NOT IN
DEFAULT UNDER THE LEASE; AND (II) THE REPRESENTATIONS AND WARRANTIES MADE BY
LESSEE PURSUANT TO OR UNDER THE LEASE ARE TRUE AND CORRECT ON THE DATE HEREOF.

     Lessee hereby authorizes Lessor to file a financing statement and
amendments thereto describing the Equipment described in this Schedule and
adding any other collateral described herein and containing any other
information required by the applicable Uniform Commercial Code. Further, Lessee
irrevocably grants to Lessor the power to sign Lessee's name and generally to
act on behalf of Lessee to execute and file financing statements and other
documents pertaining to any or all of the Equipment.

     Except as expressly modified hereby, all terms and provisions of the
Agreement shall remain in full force and effect. This Schedule is not binding or
effective with respect to the Agreement or Equipment until executed on behalf of
Lessor and Lessee by authorized representatives of Lessor and Lessee,
respectively.
<PAGE>
     IN WITNESS WHEREOF, Lessee and Lessor have caused this Schedule to be
executed by their duly authorized representatives as of the date first above
written.

LESSOR:                                  LESSEE:
GENERAL ELECTRIC CAPITAL CORPORATION     VIROLOGIC, INC.

By: /s/ John Edel                        By: /s/ William D. Young
   ------------------------------           -----------------------------

Name: John Edel                          Name: William D. Young
     ----------------------------             ---------------------------

Title: SVP                               Title: CEO
      ---------------------------              --------------------------<PAGE>
                                                                  Exhibit 10.15a
                          AMENDMENT TO RIGHTS AGREEMENT
                         BETWEEN ARADIGM CORPORATION AND

                                BANKBOSTON, N.A.

        THIS AMENDMENT TO RIGHTS AGREEMENT (this "Amendment") is made as of
October 22, 2001, by and between ARADIGM CORPORATION, a California corporation
(the "Company"), and FLEET NATIONAL BANK (F/K/A BANKBOSTON, N.A.), a national
banking association, as rights agent (the "Rights Agent").

        WHEREAS, the Company has entered into a Stock Purchase Agreement (the
"Novo Purchase Agreement") by and between the Company and Novo Nordisk
Pharmaceuticals, Inc. ("Novo Nordisk"), pursuant to which the Company will sell
shares of its Common Stock to Novo Nordisk.

        WHEREAS, the Company and the Rights Agent are parties to that certain
Rights Agreement, dated as of August 31, 1998 (the "Rights Agreement");

        WHEREAS, the Company and the Rights Agent desire to amend the Rights
Agreement to appoint EquiServe Trust Company, N.A. as the successor rights agent
under the Rights Agreement.

        WHEREAS, the Company desires to amend the Rights Agreement in connection
with the execution and delivery of the Novo Purchase Agreement; and

        WHEREAS, the Board of Directors of the Company has approved this
Amendment and authorized its appropriate officers to execute and deliver the
same to the Rights Agent.

        NOW, THEREFORE, in accordance with the procedures for amendment of the
Rights Agreement set forth in Section 27 thereof, and in consideration of the
foregoing and the mutual agreements herein set forth, the parties hereby agree
as follows:

        1. Capitalized terms that are not otherwise defined herein shall have
the meanings ascribed to them in the Rights Agreement.

        2. The definition of "Acquiring Person" set forth in Section 1(a) of the
Rights Agreement is amended by adding the following sentence to the end of that
section:

                Notwithstanding the foregoing, none of Novo Nordisk A/S, its
        Affiliates and Associates (collectively, "Novo Nordisk") shall be deemed
        to be an "Acquiring Person" for the purposes of this Agreement;
        provided, that the foregoing exemption shall cease to apply if Novo
        Nordisk becomes the Beneficial Owner of any additional Common Shares
        after the date hereof without the approval of a majority of the
        independent members of the Board of Directors of the Company other than
        in connection with the Stock Purchase Agreement dated as of October 22,
        2001 (the "Novo Purchase Agreement") by and between the Company and Novo
        Nordisk Pharmaceuticals, Inc.

        3. The definition of "Shares Acquisition Date" in Section l(n) of the
Rights Agreement is hereby deleted in its entirety and replaced with the
following:

                                       1.
<PAGE>

        "SHARES ACQUISITION DATE" shall mean the first date of public
        announcement by the Company or an Acquiring Person that an Acquiring
        Person has become such provided, however that, if such Person is
        determined not to have become an Acquiring Person pursuant to clause (y)
        of Subsection 1(a)(B) hereof or the last sentence of Section 1(a)
        hereof, then no Shares Acquisition Date shall be deemed to have
        occurred.

        4. Section 21 of the Rights Agreement is hereby deleted in its entirety
and replaced with the following:

        Change of Rights Agent. The Rights Agent or any successor Rights Agent
        may resign and be discharged from its duties under this Agreement upon
        30 days' notice in writing mailed to the Company and to each transfer
        agent for the Common Shares or Preferred Shares by registered or
        certified mail and to the holders of the Right Certificates by
        first-class mail. The Company may remove the Rights Agent or any
        successor Rights Agent upon 30 days' notice in writing mailed to the
        Rights Agent or successor Rights Agent, as the case may be, and to each
        transfer agent for the Common Shares or Preferred Shares by registered
        or certified mail, and to the holders of the Right Certificates by
        first-class mail. If the Rights Agent shall resign or be removed or
        shall otherwise become incapable of acting, the Company shall appoint a
        successor to the Rights Agent. If the Company shall fail to make such
        appointment within a period of 30 days after giving notice of such
        removal or after it has been notified in writing of such resignation or
        incapacity by the resigning or incapacitated Rights Agent or by the
        holder of a Right Certificate (who shall, with such notice, submit such
        holder's Right Certificate for inspection by the Company), then the
        registered holder of any Right Certificate may apply to any court of
        competent jurisdiction for the appointment of a new Rights Agent. Any
        successor Rights Agent, whether appointed by the Company or by such a
        court, shall be a corporation, trust company or limited liability
        company organized and doing business under the laws of the United
        States, in good standing, which is authorized under such laws to
        exercise corporate trust or stock transfer powers and is subject to
        supervision or examination by federal or state authority and which has
        individually or combined with an affiliate at the time of its
        appointment as Rights Agent a combined capital and surplus of at least
        $100 million dollars. After appointment, the successor Rights Agent
        shall be vested with the same powers, rights, duties and
        responsibilities as if it had been originally named as Rights Agent
        without further act or deed; but the predecessor Rights Agent shall
        deliver and transfer to the successor Rights Agent any property at the
        time held by it hereunder, and execute and deliver any further
        assurance, conveyance, act or deed necessary for the purpose. Not later
        than the effective date of any such appointment the Company shall file
        notice thereof in writing with the predecessor Rights Agent and each
        transfer agent for the Common Shares or Preferred Shares, and mail a
        notice thereof in writing to the registered holders of the Right
        Certificates. Failure to give any notice provided for in this Section
        21, however, or any defect therein, shall not affect the legality or
        validity of the resignation or removal of the Rights Agent or the
        appointment of the successor Rights Agent, as the case may be.

                                       2.
<PAGE>

        5. The Rights Agreement, as amended by this Amendment, shall remain in
full force and effect in accordance with its terms.

        6. All the covenants and provisions of this Amendment by or for the
benefit of the Company or the Rights Agent shall bind and inure to the benefit
of their respective successors and assigns hereunder.

        7. Nothing in this Amendment shall be construed to give to any Person
other than the Company, the Rights Agent and the registered holders of the Right
Certificates (and, prior to the Distribution Date, the Common Shares) any legal
or equitable right, remedy or claim under this Amendment; but this Amendment
shall be for the sole and exclusive benefit of the Company, the Rights Agent and
the registered holders of the Right Certificates (and, prior to the Distribution
Date, the Common Shares).

        8. If any term, provision, covenant or restriction of this Amendment is
held by a court of competent jurisdiction or other authority to be invalid, void
or unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Amendment shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.

        9. This Amendment shall be deemed to be a contract made under the laws
of the State of California and for all purposes shall be governed by and
construed in accordance with the laws of such State applicable to contracts to
be made and performed entirely within such State.

        10. This Amendment may be executed in any number of counterparts and
each of such counterparts shall for all purposes be deemed to be an original,
and all such counterparts shall together constitute but one and the same
instrument.

        11. The Company hereby certifies to the Rights Agent that this Amendment
is in compliance with Section 27 of the Rights Agreement.

                                       3.
<PAGE>

                  SIGNATURE PAGE TO RIGHTS AGREEMENT AMENDMENT

        IN WITNESS WHEREOF, the parties herein have caused this Amendment to be
duly executed and attested, all as of the date and year first above written.

                                            ARADIGM CORPORATION

                                            By: /s/ Igor Gonda
                                                -------------------------------

                                            Name: Igor Gonda
                                                  -----------------------------

                                            Title: Chief Scientific Officer
                                                   ----------------------------

Attest:

/s/ Michael Molkentin
--------------------------------
Michael Molkentin
Acting Chief Financial Officer

                                            FLEET NATIONAL BANK

                                            By:  /s/ Margaret Prentice
                                                 ------------------------------

                                            Name: Margaret Prentice
                                                  -----------------------------

                                            Title: Managing Director
                                                   ----------------------------

                  SIGNATURE PAGE TO RIGHTS AGREEMENT AMENDMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]